Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a fundamentally human skill.

See what other data-removal sites miss with Optery's free full Exposure Report that shows exactly where your information ...

The latest generation of AI models are such competent coders, engineers and (soon) scientists that many worry they may be ...

USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that ...

Recently published High-grade Glioma Market Insights report includes a comprehensive understanding of current treatment ...

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...

Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a ...

New artificial intelligence models are not only able to identify software vulnerabilities but can also instantly provide the appropriate attack tools ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...